Vishal Jajoo, of Nirmal Bang Commodities is of the view that one can buy Abbott India on correction.
Vishal Jajoo, of Nirmal Bang Commodities told CNBC-TV18, "We saw lot of multi-national companies come up with good set of numbers in this quarter. We were never discussing names like Abbott India or a Merck or maybe Sanofi India till few quarters ago. In this quarter, these companies have come up with a positive set of surprises."
"If we sees certain correction happening, Abbott India would be my first pick and in the research space we like Sun Pharma Advanced Research Company because this is a stock that has not moved the way it should be moving amongst the other pharmaceuticals stocks. The catching up exercise should act in favour of SPARC," he added.
Exclusive offer: Use code "BUDGET2020" and get Moneycontrol Pro's Subscription for as little as Rs 333/- for the first year.